Stockreport

Innate Pharma Reports First Half 2023 Financial Results and Business Update

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Phase 1/2 dose escalation safety and preliminary efficacy of ANKET® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed cli [Read more]